3 Jefferies Group Axsome Therapeutics Trades
Jefferies Group's position in Axsome Therapeutics is currently worth $25.3 Million. That's 0.56% of their equity portfolio (36th largest holding). Jefferies Group started to build up the position in Axsome Therapeutics in Q3 2023 and continued to invest until Q4 2023. Since then they sold 231 Thousand shares. The stake costed the investor $24.8 Million, netting the investor a gain of 1.8% so far.
News about Axsome Therapeutics Inc and Jefferies Group
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against First High-School, Upstart, Oscar Health, and Axsome and Encourages Investors to Contact the Firm
NEW YORK, June 19, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class ac...
Goldman Sachs Group Inc. Has $2.84 Million Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Goldman Sachs Group Inc. lowered its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 70.5% during the second quarter, according to its most recent Form 1...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Man Group plc
Man Group plc trimmed its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 80.9% during the second quarter, Holdings Channel reports. The fir...